Athira Pharma (NASDAQ:ATHA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Monday, Zacks.com reports. The brokerage currently has a $22.00 price target on the stock. Zacks Investment Research‘s price target suggests a potential upside of 18.03% from the stock’s previous close.
According to Zacks, “Athira Pharma Inc. is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. Athira Pharma Inc. is based in SEATTLE. “
NASDAQ:ATHA opened at $18.64 on Monday. Athira Pharma has a 52-week low of $15.79 and a 52-week high of $34.79. The business’s fifty day moving average is $18.45 and its 200 day moving average is $22.71.
A number of institutional investors have recently bought and sold shares of ATHA. BlackRock Inc. grew its position in Athira Pharma by 1,077.5% during the fourth quarter. BlackRock Inc. now owns 871,136 shares of the company’s stock worth $29,837,000 after buying an additional 797,152 shares in the last quarter. Northern Trust Corp purchased a new position in Athira Pharma during the fourth quarter worth about $4,977,000. Charles Schwab Investment Management Inc. purchased a new position in Athira Pharma during the fourth quarter worth about $2,869,000. PFM Health Sciences LP grew its position in Athira Pharma by 19.8% during the fourth quarter. PFM Health Sciences LP now owns 470,227 shares of the company’s stock worth $16,105,000 after buying an additional 77,738 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in Athira Pharma during the fourth quarter worth about $1,369,000. Institutional investors and hedge funds own 66.68% of the company’s stock.
About Athira Pharma
Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease.
See Also: Quiet Period Expirations
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.